{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:47:36Z","timestamp":1789145256635,"version":"build-2803163510"},"reference-count":144,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["101031962"],"award-info":[{"award-number":["101031962"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["01031317"],"award-info":[{"award-number":["01031317"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020360","name":"Infectious Diseases Society of America Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","award":["26826"],"award-info":[{"award-number":["26826"]}],"id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.biopsych.2024.09.008","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T11:47:37Z","timestamp":1726487257000},"page":"563-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders"],"prefix":"10.1016","volume":"97","author":[{"given":"Anna","family":"Onisiforou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andria","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Apostolakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Mammadov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki","family":"Mitka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Kalatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morfeas","family":"Koumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Chatzittofis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Panayiotou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polymnia","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos","family":"Zanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2024.09.008_bib1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.psychres.2017.09.021","article-title":"Factors associated with lifetime suicidal ideation and suicide attempts in outpatients with substance use disorders","volume":"262","author":"Rodr\u00edguez-Cintas","year":"2018","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2024.09.008_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.biopsych.2024.09.008_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7621","article-title":"Prevention of prescription opioid misuse and projected overdose deaths in the United States","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2024.09.008_bib4","unstructured":"EMCDDA (2023): European Drug Report 2023: Trends and Developments: European Drug Report, 1\u201398. Available at: https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2023_en."},{"key":"10.1016\/j.biopsych.2024.09.008_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0217","article-title":"The burden of opioid-related mortality in the United States","volume":"1","author":"Gomes","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2024.09.008_bib7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3389\/fpsyt.2018.00742","article-title":"Management of opioid addiction with opioid substitution treatments: Beyond methadone and buprenorphine","volume":"9","author":"Noble","year":"2018","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib8","series-title":"Global Overview of Drug Demand and Supply","year":"2017"},{"key":"10.1016\/j.biopsych.2024.09.008_bib9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Naghavi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2024.09.008_bib10","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bju.14446","article-title":"The United States opioid epidemic: A review of the surgeon\u2019s contribution to it and health policy initiatives","volume":"122","author":"Theisen","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.biopsych.2024.09.008_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.31887\/DCNS.2017.19.3\/gkoob","article-title":"Individual differences in the neuropsychopathology of addiction","volume":"19","author":"George","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: A neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.biopsych.2004.06.037","article-title":"Treatment of depression in patients with opiate dependence","volume":"56","author":"Nunes","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1151\/spp032118","article-title":"Treating adolescents for substance abuse and comorbid psychiatric disorders","volume":"2","author":"Riggs","year":"2003","journal-title":"Sci Pract Perspect"},{"key":"10.1016\/j.biopsych.2024.09.008_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.biopsych.2024.09.008_bib16","first-page":"176","article-title":"Lapse and relapse following inpatient treatment of opiate dependence","volume":"103","author":"Smyth","year":"2010","journal-title":"Ir Med J"},{"key":"10.1016\/j.biopsych.2024.09.008_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","article-title":"Efficacy of ketamine in the treatment of substance use disorders: A systematic review","volume":"9","author":"Jones","year":"2018","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib18","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1017\/S2045796019000751","article-title":"Esketamine for treatment resistant depression: A trick of smoke and mirrors?","volume":"29","author":"Gastaldon","year":"2020","journal-title":"Epidemiol Psychiatr Sci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.biopsych.2024.09.008_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269881118812095","article-title":"Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine","volume":"33","author":"Highland","year":"2019","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.biopsych.2024.09.008_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2024.09.008_bib22","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.biopsych.2016.08.039","article-title":"Reply to: Antidepressant actions of ketamine versus hydroxynorketamine","volume":"81","author":"Zanos","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib23","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cpt.3391","article-title":"A\u00a0Phase 1 assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of (2R,6R)-hydroxynorketamine in healthy volunteers","volume":"116","author":"Raja","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2024.09.008_bib24","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: Present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2024.09.008_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.biopsych.2024.09.008_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2024.09.008_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0740-5472(03)00031-X","article-title":"Long-term methadone maintenance effectiveness: Psychosocial and pharmacological variables","volume":"25","author":"Gerra","year":"2003","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2024.09.008_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fphar.2020.00401","article-title":"The effect of transcranial direct current stimulation on relapse, anxiety, and depression in patients with opioid dependence under methadone maintenance treatment: A pilot study","volume":"11","author":"Sadeghi Bimorgh","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.biopsych.2024.09.008_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugalcdep.2018.07.019","article-title":"Methadone maintenance treatment among patients exposed to illicit fentanyl in Rhode Island: Safety, dose, retention, and relapse at 6 months","volume":"192","author":"Stone","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2024.09.008_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jad.2006.09.017","article-title":"Depression in methadone maintenance treatment patients: Rate and risk factors","volume":"99","author":"Peles","year":"2007","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.biopsych.2024.09.008_bib31","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/ajad.12641","article-title":"Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders","volume":"26","author":"Romero-Gonzalez","year":"2017","journal-title":"American J Addict"},{"key":"10.1016\/j.biopsych.2024.09.008_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.drugalcdep.2005.09.004","article-title":"Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel","volume":"82","author":"Peles","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2024.09.008_bib33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11920-011-0224-0","article-title":"New findings on biological factors predicting addiction relapse vulnerability","volume":"13","author":"Sinha","year":"2011","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.biopsych.2024.09.008_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1176\/appi.ajp-rj.2019.140202","article-title":"Depression: What\u2019s buprenorphine got to do with it?","volume":"14","author":"Lynch","year":"2019","journal-title":"Am J Psychiatry Resid J"},{"key":"10.1016\/j.biopsych.2024.09.008_bib35","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1176\/appi.ajp.2009.09020149","article-title":"Effect of acute antidepressant administration on negative affective bias in depressed patients","volume":"166","author":"Harmer","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00007691-199402000-00006","article-title":"Probable metabolic interaction between methadone and fluvoxamine in addict patients","volume":"16","author":"Bertschy","year":"1994","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.biopsych.2024.09.008_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1300\/J069v18n04_02","article-title":"A\u00a0therapeutic use of the methadone fluvoxamine drug interaction","volume":"18","author":"DeMaria","year":"1999","journal-title":"J\u00a0Addict Dis"},{"key":"10.1016\/j.biopsych.2024.09.008_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jsat.2006.03.012","article-title":"Depression among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS)","volume":"30","author":"Havard","year":"2006","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2024.09.008_bib39","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/add.12860","article-title":"Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome Study","volume":"110","author":"Teesson","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2024.09.008_bib40","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14001","article-title":"Association between receipt of antidepressants and retention in buprenorphine treatment for opioid use disorder: A population-based retrospective cohort study","volume":"83","author":"Zhang","year":"2022","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnbeh.2020.00075","article-title":"Ketamine blocks morphine-induced conditioned place preference and anxiety-like behaviors in mice","volume":"14","author":"McKendrick","year":"2020","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0024-3205(00)00639-1","article-title":"Effects of the non-competitive NMDA receptor antagonist ketamine on morphine-induced place preference in mice","volume":"67","author":"Suzuki","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FBP.0b013e3282fe88a0","article-title":"Effects of scopolamine and ketamine on reconsolidation of morphine conditioned place preference in rats","volume":"19","author":"Zhai","year":"2008","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2024.09.008_bib44","article-title":"(2R,6R)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice","author":"Michael","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopsych.2024.09.008_bib45","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.npp.1300342","article-title":"Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers","volume":"29","author":"Morgan","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00213-005-0001-z","article-title":"Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: The effects of levels of processing at encoding and of the subsequent retrieval task","volume":"181","author":"Honey","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fnbeh.2019.00134","article-title":"Individual vulnerability to stress is associated with increased demand for intravenous heroin self-administration in rats","volume":"13","author":"Stafford","year":"2019","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172927","article-title":"R-(\u2212)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder1","volume":"194","author":"Witkin","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2024.09.008_bib49","first-page":"33","article-title":"Interactions of ketamine, naloxone and morphine in the rat","volume":"39","author":"Fidecka","year":"1987","journal-title":"Pol J Pharmacol Pharm"},{"key":"10.1016\/j.biopsych.2024.09.008_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.110987","article-title":"The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement","volume":"253","author":"Drinkuth","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2024.09.008_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106279","article-title":"Ketamine metabolite alleviates morphine withdrawal-induced anxiety via modulating nucleus accumbens parvalbumin neurons in male mice","volume":"186","author":"Chen","year":"2023","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.biopsych.2024.09.008_bib52","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1213\/01.ane.0000202382.82847.64","article-title":"S(+)-ketamine attenuates increase in electroencephalograph activity and amplitude height of sensory-evoked potentials during rapid opioid detoxification","volume":"102","author":"Freye","year":"2006","journal-title":"Anesth Analg"},{"key":"10.1016\/j.biopsych.2024.09.008_bib53","first-page":"625","article-title":"Effects of ketamine on precipitated opiate withdrawal","volume":"42","author":"Jovaisa","year":"2006","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.biopsych.2024.09.008_bib54","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A\u00a0double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib55","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41398-020-00897-0","article-title":"A\u00a0randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression","volume":"10","author":"Shiroma","year":"2020","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib56","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41386-019-0570-x","article-title":"Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression","volume":"45","author":"Phillips","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib57","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.annemergmed.2022.08.183","article-title":"159 Ketamine use for buprenorphine-precipitated opioid withdrawal: A case series of 10 patients","volume":"80","author":"Heeney","year":"2022","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.biopsych.2024.09.008_bib58","first-page":"483","article-title":"Synergistic effect of ketamine and buprenorphine observed in the treatment of buprenorphine precipitated opioid withdrawal in a patient with fentanyl use","volume":"16","author":"Hailozian","year":"2022","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.biopsych.2024.09.008_bib59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2024.09.008_bib60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence","volume":"39","author":"Krupitsky","year":"2007","journal-title":"J\u00a0Psychoact Drugs"},{"key":"10.1016\/j.biopsych.2024.09.008_bib61","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1526-4637.2012.01486.x","article-title":"The use of a subanesthetic infusion of intravenous ketamine to allow withdrawal of medically prescribed opioids in people with chronic pain, opioid tolerance and hyperalgesia: Outcome at 6 months","volume":"13","author":"Quinlan","year":"2012","journal-title":"Pain Med"},{"key":"10.1016\/j.biopsych.2024.09.008_bib62","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/papr.12829","article-title":"Ketamine and cognitive behavioral therapy for rapid opioid tapering with sustained opioid abstinence: A case report and 1-year follow-up","volume":"20","author":"Ocker","year":"2020","journal-title":"Pain Pract"},{"key":"10.1016\/j.biopsych.2024.09.008_bib63","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12888-016-1112-2","article-title":"Experience of the use of ketamine to manage opioid withdrawal in an addicted woman: A case report","volume":"16","author":"Lalanne","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib64","first-page":"488","article-title":"Precipitated opioid withdrawal treated with ketamine in a hospitalized patient: A case report","volume":"17","author":"Christian","year":"2023","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.biopsych.2024.09.008_bib65","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/00000542-200605000-00043","article-title":"Use of ketamine to facilitate opioid withdrawal in a child","volume":"104","author":"Ito","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1876386301104010001","article-title":"Use of ketamine in ameliorating opioid withdrawal symptoms during an induction phase of buprenorphine","volume":"4","author":"Omoigui","year":"2011","journal-title":"Open Pain J"},{"key":"10.1016\/j.biopsych.2024.09.008_bib67","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ilar.52.3.342","article-title":"Opioid dependence and NMDA receptors","volume":"52","author":"Glass","year":"2011","journal-title":"ILAR J"},{"key":"10.1016\/j.biopsych.2024.09.008_bib68","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0896-6273(03)00461-6","article-title":"Corticotropin-releasing factor requires CRF binding protein to potentiate NMDA receptors via CRF receptor 2 in dopamine neurons","volume":"39","author":"Ungless","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2024.09.008_bib69","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0306-4522(94)00335-3","article-title":"Expression patterns of a glutamate-binding protein in the rat central nervous system: Comparison with N-methyl-D-aspartate receptor subunit 1 in rat","volume":"64","author":"Sato","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2024.09.008_bib70","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1523\/JNEUROSCI.14-02-00667.1994","article-title":"Light and electron microscope distribution of the NMDA receptor subunit NMDAR1 in the rat nervous system using a selective anti-peptide antibody","volume":"14","author":"Petralia","year":"1994","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib71","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/(SICI)1096-9861(19990614)408:4<549::AID-CNE8>3.0.CO;2-3","article-title":"Frequent colocalization of mu opioid and NMDA-type glutamate receptors at postsynaptic sites in periaqueductal gray neurons","volume":"408","author":"Commons","year":"1999","journal-title":"J\u00a0Comp Neurol"},{"key":"10.1016\/j.biopsych.2024.09.008_bib72","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuroscience.2009.07.020","article-title":"Ultrastructural relationship between N-methyl-D-aspartate-NR1 receptor subunit and mu-opioid receptor in the mouse central nucleus of the amygdala","volume":"163","author":"Glass","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2024.09.008_bib73","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1523\/JNEUROSCI.17-12-04839.1997","article-title":"Dual ultrastructural localization of mu-opioid receptors and NMDA-type glutamate receptors in the shell of the rat nucleus accumbens","volume":"17","author":"Gracy","year":"1997","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib74","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0361-9230(00)00415-9","article-title":"Ultrastructural evidence for presynaptic Mu Opioid receptor modulation of synaptic plasticity in NMDA-receptor-containing dendrites in the dentate gyrus","volume":"54","author":"Milner","year":"2001","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.biopsych.2024.09.008_bib75","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0165-0173(99)00020-X","article-title":"NMDA and opioid receptors: Their interactions in antinociception, tolerance and neuroplasticity","volume":"30","author":"Mao","year":"1999","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.biopsych.2024.09.008_bib76","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/cercor\/bhq060","article-title":"NMDA receptor hypofunction in the prelimbic cortex increases sensitivity to the rewarding properties of opiates via dopaminergic and amygdalar substrates","volume":"21","author":"Bishop","year":"2011","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.biopsych.2024.09.008_bib77","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1007\/s00213-014-3616-0","article-title":"NMDA Receptor Blockade in the Prelimbic Cortex Activates the Mesolimbic System and Dopamine-Dependent Opiate Reward Signaling","volume":"231","author":"Tan","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib78","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s11064-004-6884-y","article-title":"NMDA receptor in nucleus accumbens is implicated in morphine withdrawal in rats","volume":"29","author":"Ji","year":"2004","journal-title":"Neurochem Res"},{"key":"10.1016\/j.biopsych.2024.09.008_bib79","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0091-3057(92)90181-E","article-title":"Effects of MK 801 on morphine physical dependence: Attenuation and intensification","volume":"43","author":"Koyuncuo\u011flu","year":"1992","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2024.09.008_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130100739","article-title":"The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans","volume":"157","author":"Bisaga","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib81","first-page":"147","article-title":"The treatment of heroin addicts with dextromethorphan: A double-blind comparison of dextromethorphan with chlorpromazine","volume":"28","author":"Koyuncuoglu","year":"1990","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.biopsych.2024.09.008_bib82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neucli.2004.11.001","article-title":"Increase in delta- and beta-wave activity of the EEG during rapid opiate detoxification (ROD)-reversal by administration of the non-specific NMDA-antagonist S+\u00a0ketamine-","volume":"35","author":"Freye","year":"2005","journal-title":"Neurophysiol Clin"},{"key":"10.1016\/j.biopsych.2024.09.008_bib83","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0304-3959(95)00073-2","article-title":"Mechanisms of hyperalgesian and morphine tolerance: A current view of their possible interactions","volume":"62","author":"Mao","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.biopsych.2024.09.008_bib84","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0304-3959(96)03120-X","article-title":"Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats","volume":"67","author":"Mao","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.biopsych.2024.09.008_bib85","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1124\/jpet.115.227629","article-title":"Phosphorylation of the N-methyl-d-aspartate receptor is increased in the nucleus accumbens during both acute and extended morphine withdrawal","volume":"355","author":"Anderson","year":"2015","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2024.09.008_bib86","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0304-3959(95)00023-L","article-title":"The development of morphine tolerance and dependence is associated with translocation of protein kinase C","volume":"61","author":"Mayer","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.biopsych.2024.09.008_bib87","doi-asserted-by":"crossref","DOI":"10.1101\/2020.12.20.423680","article-title":"Prolonged withdrawal from escalated oxycodone is associated with increased expression of glutamate receptors in the rat hippocampus","volume":"14","author":"Salisbury","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib88","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.pnpbp.2008.10.005","article-title":"Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression","volume":"33","author":"Feyissa","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib89","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/sj.npp.1301312","article-title":"Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders","volume":"32","author":"Beneyto","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib90","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biopsych.2019.07.027","article-title":"The negative affect of protracted opioid abstinence: Progress and perspectives from rodent models","volume":"87","author":"Welsch","year":"2020","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib91","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1523\/JNEUROSCI.1316-22.2022","article-title":"NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine","volume":"43","author":"Zanos","year":"2023","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib92","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0006-8993(82)90454-1","article-title":"Reinforcing effects of morphine in the nucleus accumbens","volume":"237","author":"Olds","year":"1982","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2024.09.008_bib93","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0166-2236(92)90171-4","article-title":"Neural substrates of opiate withdrawal","volume":"15","author":"Koob","year":"1992","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib94","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/371155a0","article-title":"Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome","volume":"371","author":"Harris","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2024.09.008_bib95","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nature16954","article-title":"A\u00a0thalamic input to the nucleus accumbens mediates opiate dependence","volume":"530","author":"Zhu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2024.09.008_bib96","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0893-133X(96)00094-2","article-title":"A\u00a0selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal","volume":"15","author":"Rasmussen","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib97","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1523\/JNEUROSCI.21-12-04451.2001","article-title":"Morphine-induced dependence and sensitization are altered in mice deficient in AMPA-type glutamate receptor-A subunits","volume":"21","author":"Vekovischeva","year":"2001","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib98","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1523\/JNEUROSCI.2875-12.2016","article-title":"Nucleus accumbens AMPA receptors are necessary for morphine-withdrawal-induced negative-affective states in rats","volume":"36","author":"Russell","year":"2016","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib99","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.neuroscience.2006.10.018","article-title":"Opiate withdrawal modifies synaptic plasticity in subicular\u2013nucleus accumbens pathway in\u00a0vivo","volume":"144","author":"Dong","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2024.09.008_bib100","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/mp.2017.239","article-title":"Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit","volume":"23","author":"Yao","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib101","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw011","article-title":"Emotional Impairment and Persistent Upregulation of mGlu5 Receptor following morphine Abstinence: Implications of an mGlu5-MOPr Interaction","volume":"19","author":"Zanos","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2024.09.008_bib102","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/mp.2017.58","article-title":"Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: An [11C]ABP688 and PET imaging study in depression","volume":"23","author":"Esterlis","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib103","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Phys"},{"key":"10.1016\/j.biopsych.2024.09.008_bib104","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00000542-199901000-00023","article-title":"Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells","volume":"90","author":"Hirota","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0773.1995.tb01041.x","article-title":"Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors","volume":"77","author":"Hustveit","year":"1995","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.biopsych.2024.09.008_bib106","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","article-title":"Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats","volume":"210","author":"Nemeth","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib107","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1038\/s41380-022-01673-w","article-title":"Target deconvolution studies of (2R,6R)-hydroxynorketamine: An elusive search","volume":"27","author":"Bonaventura","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib108","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainres.2014.03.026","article-title":"Central antinociception induced by ketamine is mediated by endogenous opioids and \u03bc- and \u03b4-opioid receptors","volume":"1562","author":"Pacheco","year":"2014","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2024.09.008_bib109","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","author":"Klein","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.biopsych.2024.09.008_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173228","article-title":"Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice","volume":"208","author":"Zhang","year":"2021","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2024.09.008_bib111","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: Implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib112","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.biopsych.2022.12.019","article-title":"Mu Opioid receptor activation mediates (S)-ketamine reinforcement in rats: Implications for abuse liability","volume":"93","author":"Levinstein","year":"2023","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib113","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/s41467-024-45157-7","article-title":"Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats","volume":"15","author":"Di Ianni","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.biopsych.2024.09.008_bib114","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib115","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","article-title":"Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism","volume":"24","author":"Williams","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib116","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.biopsych.2018.11.006","article-title":"Lack of opioid system in the antidepressant actions of ketamine","volume":"85","author":"Zhang","year":"2019","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib117","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","article-title":"Association of Combined naltrexone and ketamine with Depressive Symptoms in a Case series of Patients with Depression and Alcohol Use Disorder","volume":"76","author":"Yoon","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib118","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.biopsych.2019.02.008","article-title":"Concurrent use of buprenorphine, methadone, or naltrexone does not inhibit ketamine\u2019s antidepressant activity","volume":"85","author":"Marton","year":"2019","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.919773","article-title":"Opioid receptor-mediated regulation of neurotransmission in the brain","volume":"15","author":"Reeves","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib120","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2021.12.003","article-title":"BDNF signaling in context: From synaptic regulation to psychiatric disorders","volume":"185","author":"Wang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.biopsych.2024.09.008_bib121","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fncel.2019.00363","article-title":"Brain-derived neurotrophic factor: A key molecule for memory in the healthy and the pathological brain","volume":"13","author":"Miranda","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib122","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.bbrc.2017.05.157","article-title":"Ketamine induces brain-derived neurotrophic factor expression via phosphorylation of histone deacetylase 5 in rats","volume":"489","author":"Choi","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.biopsych.2024.09.008_bib123","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1017\/S1461145713001119","article-title":"Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression","volume":"17","author":"Haile","year":"2014","journal-title":"Int J Neuropsychopharm"},{"key":"10.1016\/j.biopsych.2024.09.008_bib124","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41386-023-01629-w","article-title":"Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms","volume":"49","author":"Krystal","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib125","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib126","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41597-024-03538-z","article-title":"Molecular signatures of premature aging in Major Depression and Substance Use Disorders","volume":"11","author":"Onisiforou","year":"2024","journal-title":"Sci Data"},{"key":"10.1016\/j.biopsych.2024.09.008_bib127","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"(2R,6R)-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.biopsych.2024.09.008_bib128","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/pr.111.005108","article-title":"Brain-derived neurotrophic factor and neuropsychiatric disorders","volume":"64","author":"Autry","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.biopsych.2024.09.008_bib129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2024.09.008_bib130","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.biopsych.2012.09.006","article-title":"The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine","volume":"73","author":"Monteggia","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.09.008_bib131","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1038\/s41467-018-04439-7","article-title":"The CaMKII\/NMDA receptor complex controls hippocampal synaptic transmission by kinase-dependent and independent mechanisms","volume":"9","author":"Incontro","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.biopsych.2024.09.008_bib132","article-title":"Brain-derived neurotrophic factor scales presynaptic calcium transients to modulate excitatory neurotransmission","volume":"121","author":"Wang","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.biopsych.2024.09.008_bib133","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib134","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2024.09.008_bib135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0079-6123(08)60453-7","article-title":"The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer\u2019s disease","volume":"116","author":"Farber","year":"1998","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.biopsych.2024.09.008_bib136","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: Evidence and potential mechanisms","volume":"142","author":"Ivan Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib137","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jpsychires.2022.04.035","article-title":"The abuse liability of ketamine: A scoping review of preclinical and clinical studies","volume":"151","author":"Le","year":"2022","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.biopsych.2024.09.008_bib138","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1111\/bph.14683","article-title":"(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses","volume":"176","author":"Zanos","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2024.09.008_bib139","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1038\/nature22085","article-title":"Zanos, et\u00a0al. Reply","volume":"546","author":"Zanos","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2024.09.008_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2023.173531","article-title":"Role of group II metabotropic glutamate receptors in ketamine\u2019s antidepressant actions","volume":"223","author":"Onisiforou","year":"2023","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2024.09.008_bib141","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1073\/pnas.1816071116","article-title":"Antidepressant-relevant concentrations of the ketamine metabolite (2 R,6 R)-hydroxynorketamine do not block NMDA receptor function","volume":"116","author":"Lumsden","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.biopsych.2024.09.008_bib142","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/npp.2016.210","article-title":"Ketamine mechanism of action: Separating the wheat from the chaff","volume":"42","author":"Gould","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.09.008_bib143","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41591-019-0723-9","article-title":"Visualization of AMPA receptors in living human brain with positron emission tomography","volume":"26","author":"Miyazaki","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2024.09.008_bib144","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13550-018-0424-2","article-title":"First in human evaluation of [18F]PK-209, a PET ligand for the ion channel binding site of NMDA receptors","volume":"8","author":"van der Aart","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.biopsych.2024.09.008_bib145","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2967\/jnumed.112.107995","article-title":"18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: A first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry","volume":"54","author":"Wong","year":"2013","journal-title":"J\u00a0Nucl Med"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322324015919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322324015919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:55:41Z","timestamp":1778241341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322324015919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":144,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0006322324015919"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2024.09.008","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2024.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}